Skip to main content

Advertisement

SpringerLink
Log in

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review

  • Invited Review
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC), against a background of lack of evidence following the introduction of targeted therapy.

Methods

A literature review was performed in January 2017 using the MEDLINE/PubMed and EMBASE databases. The PRISMA guidelines were followed for conduct of the study. Two authors independently screened the 270 papers retrieved from the search, and the finally selected publications were identified by consensus between the two reviewers. A total of 55 studies were included in the present review.

Results

Globally, the indications for CN have decreased over recent years. Although current guidelines consider CN an adequate option in selected patients based on prospective studies in the cytokine era, evidence for CN in the era of targeted therapy is based on retrospective studies only.

Conclusions

The results of ongoing prospective studies are still awaited. Retrospective data suggest that young male patients with oligometastatic disease and a good performance status can be considered suitable surgical candidates who may benefit from CN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. doi:10.1016/j.eururo.2015.01.005

    Article  PubMed  Google Scholar 

  2. Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, Lundstam S (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48(3):231–238. doi:10.3109/21681805.2013.864698

    Article  PubMed  Google Scholar 

  3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220–241. doi:10.3322/caac.21149

    Article  PubMed  Google Scholar 

  4. Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, Powles T, Sternberg C, Bex A (2015) A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol 67(1):100–110. doi:10.1016/j.eururo.2014.04.006

    Article  PubMed  Google Scholar 

  5. Calvo E, Schmidinger M, Heng DY, Grunwald V, Escudier B (2016) Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev 50:109–117. doi:10.1016/j.ctrv.2016.09.002

    Article  PubMed  Google Scholar 

  6. Howick J, Chalmers I, Glasziou P (2011) Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). OCEBM

  7. Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM, Rosenberg SA, Walther MM (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150(2 Pt 1):463–466

    Article  CAS  PubMed  Google Scholar 

  8. Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA et al (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 108(4):518–523

    Article  CAS  PubMed  Google Scholar 

  9. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for R, Treatment of Cancer Genitourinary G (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970

    Article  CAS  PubMed  Google Scholar 

  10. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3):1071–1076. doi:10.1097/01.ju.0000110610.61545.ae

    Article  PubMed  Google Scholar 

  11. Culp SH (2015) Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol 7(5):275–285. doi:10.1177/1756287215585501

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bex A, Ljungberg B, van Poppel H, Powles T, European Association of U (2016) The role of cytoreductive nephrectomy: European Association of Urology Recommendations in 2016. Eur Urol 70(6):901–905. doi:10.1016/j.eururo.2016.07.005

    Article  PubMed  Google Scholar 

  13. Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD (2012) Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer 10(3):159–163. doi:10.1016/j.clgc.2012.03.008

    Article  PubMed  PubMed Central  Google Scholar 

  14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi:10.1056/NEJMoa065044

    Article  CAS  PubMed  Google Scholar 

  15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Group TS (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. doi:10.1056/NEJMoa060655

    Article  CAS  PubMed  Google Scholar 

  16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281. doi:10.1056/NEJMoa066838

    Article  CAS  PubMed  Google Scholar 

  17. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. doi:10.1016/S0140-6736(08)61039-9

    Article  CAS  PubMed  Google Scholar 

  18. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150. doi:10.1200/JCO.2009.26.7849

    Article  CAS  PubMed  Google Scholar 

  19. Serie DJ, Joseph RW, Cheville JC, Ho TH, Parasramka M, Hilton T, Thompson RH, Leibovich BC, Parker AS, Eckel-Passow JE (2016) Clear cell type A and B molecular subtypes in metastatic clear cell renal cell carcinoma: tumor heterogeneity and aggressiveness. Eur Urol. doi:10.1016/j.eururo.2016.11.018

    PubMed  Google Scholar 

  20. Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA (2015) Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol 33(12):528–537. doi:10.1016/j.urolonc.2015.10.003

    Article  PubMed  Google Scholar 

  21. Li H, Samawi H, Heng DY (2015) The use of prognostic factors in metastatic renal cell carcinoma. Urol Oncol 33(12):509–516. doi:10.1016/j.urolonc.2015.08.003

    Article  PubMed  Google Scholar 

  22. Tang PA, Vickers MM, Heng DY (2011) Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am 25(4):871–891. doi:10.1016/j.hoc.2011.04.003

    Article  PubMed  Google Scholar 

  23. Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66(4):704–710. doi:10.1016/j.eururo.2014.05.034

    Article  PubMed  Google Scholar 

  24. Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int 106(9):1266–1269. doi:10.1111/j.1464-410X.2010.09323.x

    Article  CAS  PubMed  Google Scholar 

  25. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540. doi:10.1200/JCO.1999.17.8.2530

    Article  CAS  PubMed  Google Scholar 

  26. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. doi:10.1200/JCO.2008.21.4809

    Article  CAS  PubMed  Google Scholar 

  27. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148. doi:10.1016/S1470-2045(12)70559-4

    Article  PubMed  PubMed Central  Google Scholar 

  28. Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ (2015) Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol 33(8):339, e339–e315. doi:10.1016/j.urolonc.2015.05.014

    Article  Google Scholar 

  29. Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, Brooks JD, Srinivas S, Leppert JT (2014) Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer 134(9):2245–2252. doi:10.1002/ijc.28553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ (2014) Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res 34(5):2405–2411

    PubMed  Google Scholar 

  31. Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK (2014) Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int 113(5b):e67–e74. doi:10.1111/bju.12442

    Article  PubMed  PubMed Central  Google Scholar 

  32. Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, Choueiri TK (2016) Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base study. J Clin Oncol 34(27):3267–3275. doi:10.1200/JCO.2016.66.7931

    Article  PubMed  PubMed Central  Google Scholar 

  33. Bamias A, Tzannis K, Papatsoris A, Oudard S, Beuselinck B, Escudier B, Liontos M, Elaidi TR, Chrisofos M, Stravodimos K, Anastasiou I, Mitropoulos D, Deliveliotis C, Constantinides C, Dimopoulos MA, Bamia C (2014) Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. Clin Genitourin Cancer 12(5):373–383. doi:10.1016/j.clgc.2014.03.012

    Article  PubMed  Google Scholar 

  34. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185(1):60–66. doi:10.1016/j.juro.2010.09.012

    Article  PubMed  Google Scholar 

  35. de Groot S, Redekop WK, Sleijfer S, Oosterwijk E, Bex A, Kiemeney LA, Uyl-de Groot CA (2016) Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: results from a population-based registry. Urology 95:121–127. doi:10.1016/j.urology.2016.04.042

    Article  PubMed  Google Scholar 

  36. Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, Ost P, Devisschere P, Villeirs G, Fonteyne V, Decaestecker K (2017) The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: prognostic features in the era of targeted therapies. Urol Oncol. doi:10.1016/j.urolonc.2016.10.013

    PubMed  Google Scholar 

  37. Petrelli F, Coinu A, Vavassori I, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S (2016) Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer 14(6):465–472. doi:10.1016/j.clgc.2016.04.001

    Article  PubMed  Google Scholar 

  38. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. doi:10.1056/NEJMoa1510665

    Article  CAS  PubMed  Google Scholar 

  39. Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ, CheckMate i (2017) CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. doi:10.1016/j.eururo.2017.02.010

    Google Scholar 

  40. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659. doi:10.1056/NEJMoa003013

    Article  CAS  PubMed  Google Scholar 

  41. AP-Hd P (2009) Clinical trial to assess the importance of nephrectomy (CARMENA) 2009. https://clinicaltrials.gov/ct2/show/record/NCT00930033?term=carmena&rank=1

  42. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  43. Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Mejean A, Nathan P, Oades G, Patard JJ, Paul J, Ravaud A, Escudier B, Renal Cross Channel G (2017) Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. Eur Urol 71(6):845–847. doi:10.1016/j.eururo.2016.10.029

    Article  PubMed  Google Scholar 

  44. Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI, Sun M (2013) In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol 63(6):1107–1114. doi:10.1016/j.eururo.2012.08.069

    Article  PubMed  Google Scholar 

  45. Jackson BL, Fowler S, Williams ST, British Association of Urological Surgeons-Section of O (2015) Perioperative outcomes of cytoreductive nephrectomy in the UK in 2012. BJU Int 116(6):905–910. doi:10.1111/bju.12890

    Article  PubMed  Google Scholar 

  46. Silberstein JL, Adamy A, Maschino AC, Ehdaie B, Garg T, Favaretto RL, Ghoneim TP, Motzer RJ, Russo P (2012) Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). BJU Int 110(9):1276–1282. doi:10.1111/j.1464-410X.2012.11103.x

    Article  PubMed  PubMed Central  Google Scholar 

  47. Gershman B, Moreira DM, Boorjian SA, Lohse CM, Cheville JC, Costello BA, Leibovich BC, Thompson RH (2016) Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol 69(1):84–91. doi:10.1016/j.eururo.2015.05.022

    Article  PubMed  Google Scholar 

  48. Nunez Bragayrac L, Hoffmeyer J, Abbotoy D, Attwood K, Kauffman E, Spiess P, Wagner A, Schwaab T (2016) Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. World J Urol 34(12):1651–1656. doi:10.1007/s00345-016-1827-1

    Article  PubMed  Google Scholar 

  49. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM (2001) Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 166(1):68–72

    Article  CAS  PubMed  Google Scholar 

  50. Trinh QD, Sukumar S, Schmitges J, Bianchi M, Sun M, Shariat SF, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI (2013) Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. Ann Surg Oncol 20(6):2096–2102. doi:10.1245/s10434-012-2806-4

    Article  PubMed  Google Scholar 

  51. Patel HD, Gorin MA, Gupta N, Kates M, Johnson MH, Pierorazio PM, Allaf ME (2016) Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. Can Urol Assoc J 10(11–12):389–395. doi:10.5489/cuaj.1999

    Article  PubMed  PubMed Central  Google Scholar 

  52. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169(6):2076–2083. doi:10.1097/01.ju.0000066130.27119.1c

    Article  PubMed  Google Scholar 

  53. Lughezzani G, Capitanio U, Jeldres C, Isbarn H, Shariat SF, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz PI (2009) Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer 115(24):5680–5687. doi:10.1002/cncr.24682

    Article  PubMed  Google Scholar 

  54. Gershman B, Thompson RH, Moreira DM, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC (2017) Lymph node dissection is not associated with improved survival among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma: a propensity score based analysis. J Urol 197(3 Pt 1):574–579. doi:10.1016/j.juro.2016.09.074

    Article  PubMed  Google Scholar 

  55. Feuerstein MA, Kent M, Bernstein M, Russo P (2014) Lymph node dissection during cytoreductive nephrectomy: a retrospective analysis. Int J Urol 21(9):874–879. doi:10.1111/iju.12457

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Fundació Puigvert, C/Cartagena, 340-350, 08025, Barcelona, Spain

    Oscar Rodriguez Faba, Alberto Breda, Francesca Pisano, José Daniel Subiela, Francesco Sanguedolce & Joan Palou

  2. Department of Urology, LMU Munich, Munich, Germany

    Sabine D. Brookman-May

  3. Hospital Universitario La Paz, Madrid, Spain

    Estefania Linares

  4. Department of Urology, A.S.L. Modena, Bernardino Ramazzini Hospital, Carpi, Italy

    Maurizio Brausi

Authors
  1. Oscar Rodriguez Faba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabine D. Brookman-May
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Estefania Linares
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberto Breda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesca Pisano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. José Daniel Subiela
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesco Sanguedolce
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maurizio Brausi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joan Palou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Protocol/project development: ORF; Data collection or management ORF: FP; Data analysis: ORF, FP, JDS, SBM, EL, FS; Manuscript writing/editing: all authors

Corresponding author

Correspondence to Oscar Rodriguez Faba.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

For this type of study formal consent is not required.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Oscar Rodriguez Faba, Sabine D. Brookman-May, Estefania Linares and Maurizio Brausi are Members of the Renal Cancer Subcommittee of the ESOU-EAU (European Society of Uro-Oncology).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Faba, O.R., Brookman-May, S.D., Linares, E. et al. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review. World J Urol 35, 1807–1816 (2017). https://doi.org/10.1007/s00345-017-2072-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-017-2072-y

Keywords

Search

Navigation